GHK-Cu cosmetic ingredient of skin care creams and cheeses, permitted in the EU under the Cosmetic Regulation (EC 1223/2009)
A double-blind placebo-controlled study of exenatide for the treatment of weight gain associated with olanzapine in overweight or obese adults with bipolar disorder, major depressive disorder, schizophrenia or schizoaffective disorder
The New England Journal of Medicine, 336(13), 844-848
This pharmacovigilance system allows patients, carers, and healthcare professionals to report any suspected side effects from medicines, vaccines, and medical devices including those that are unlicensed or used off-label
Safety Considerations and Provider Eligibility Assessment Women over 50 considering GLP-1 therapy should be evaluated for personal and family history of medullary thyroid cancer, pancreatitis, severe kidney disease, and cardiovascular stability